Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.

MLA

Berger, Stefan P., et al. “Two-Year Outcomes in de Novo Renal Transplant Recipients Receiving Everolimus-Facilitated Calcineurin Inhibitor Reduction Regimen from the TRANSFORM Study.” American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 19, no. 11, Nov. 2019, pp. 3018–34. EBSCOhost, https://doi.org/10.1111/ajt.15480.

APA

Berger, S. P., Sommerer, C., Witzke, O., Tedesco, H., Chadban, S., Mulgaonkar, S., Qazi, Y., de Fijter, J. W., Oppenheimer, F., Cruzado, J. M., Watarai, Y., Massari, P., Legendre, C., Citterio, F., Henry, M., Srinivas, T. R., Vincenti, F., Gutierrez, M. P. H., Marti, A. M., … Pascual, J. (2019). Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 19(11), 3018–3034. https://doi.org/10.1111/ajt.15480

Chicago

Berger, Stefan P, Claudia Sommerer, Oliver Witzke, Helio Tedesco, Steve Chadban, Shamkant Mulgaonkar, Yasir Qazi, et al. 2019. “Two-Year Outcomes in de Novo Renal Transplant Recipients Receiving Everolimus-Facilitated Calcineurin Inhibitor Reduction Regimen from the TRANSFORM Study.” American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 19 (11): 3018–34. doi:10.1111/ajt.15480.